Table 3.
Univariate and multivariate analyses for recurrence-free survival and overall survival in patients undergoing liver metastasectomy.
| Parameters | RFS | OS | ||||||
|---|---|---|---|---|---|---|---|---|
| Univariate | Multivariate | Univariate | Multivariate | |||||
| HR (95% CI) | p Value | HR (95% CI) | p Value | HR (95% CI) | p Value | HR (95% CI) | p Value | |
| Age (>60 years vs. ≤60 years) | 0.968 (0.582–1.610) | 0.901 | 1.264 (0.664–2.408) | 0.475 | ||||
| Sex (male vs. female) | 1.076 (0.647–1.789) | 0.778 | 0.888 (0.466–1.693) | 0.718 | ||||
| Primary tumour location (rectum vs. colon) | 1.302 (0.788–2.152) | 0.303 | 1.361 (0.718–2.581) | 0.345 | ||||
| Primary tumour differentiation (poor vs. well to moderate) | 1.327 (0.773–2.277) | 0.305 | 0.835 (0.382–1.824) | 0.652 | ||||
| T stage (4 vs. 1–3) | 1.341 (0.813–2.212) | 0.250 | 1.524 (0.802–2.896) | 0.199 | ||||
| N stage (1–2 vs. 0) | 1.844 (1.044–3.256) | 0.035 | 1.806 (1.018–3.202) | 0.043 | 1.922 (0.909–4.067) | 0.087 | 2.041(0.960–4.338) | 0.064 |
| Timing of metastasis (synchronous vs. metachronous) | 1.220 (0.718–2.074) | 0.463 | 1.245 (0.628–2.470) | 0.531 | ||||
| Metastases diameter (>3 cm vs. ≤3 cm) | 1.576 (0.943–2.634) | 0.083 | 1.533 (0.915–2.568) | 0.105 | 1.870 (0.986–3.547) | 0.055 | 1.738 (0.915–3.300) | 0.091 |
| Preoperative CEA (>50 ng/mL vs. ≤50 ng/mL) | 1.477 (0.810–2.694) | 0.204 | 1.796 (0.878–3.674) | 0.109 | ||||
| Adjuvant chemotherapy (yes vs. no) | 1.794 (0.973–3.307) | 0.061 | 1.666 (0.900–3.081) | 0.104 | 1.567 (0.688–3.570) | 0.285 | ||
| Intratumoural CD8/CD3 ratio (high vs. low) | 0.585 (0.353–0.968) | 0.037 | 0.593 (0.357–0.985) | 0.043 | 0.392 (0.193–0.793) | 0.009 | 0.391 (0.193–0.794) | 0.009 |
Abbreviations: CEA, carcinoembryonic antigen; RFS, recurrence-free survival; OS, overall survival; HR, hazard ratios; CI, confidence interval. Disease stage was classified according to the 2010 American Joint Committee on Cancer/International Union Against Cancer (AJCC/UICC) staging system.